Showing 9,461 - 9,480 results of 226,405 for search '(( a ((a decrease) OR (linear decrease)) ) OR ( a ((greater decrease) OR (largest decrease)) ))', query time: 1.04s Refine Results
  1. 9461

    PowerPoint Slides for: Rapamycin Enhances Repressed Autophagy and Attenuates Aggressive Progression in a Rat Model of IgA Nephropathy by Liu D. (3800659)

    Published 2017
    “…<p><b><i>Background:</i></b> IgA nephropathy (IgAN) has been considered to be the most frequent form of primary glomerulonephritis that occurs worldwide with a variety of factors involved in its occurrence and development. …”
  2. 9462

    Data Sheet 3_Identification of the malonylation modification in Staphylococcus aureus and insight into the regulators in biofilm formation.pdf by Xiaoyan Yu (319080)

    Published 2025
    “…In particular, the response regulator, AgrA, showed decreased expression but increased malonylation at the K2, K11, and K216 sites during S. aureus biofilm formation, suggesting functional compensation. …”
  3. 9463

    Data Sheet 2_Identification of the malonylation modification in Staphylococcus aureus and insight into the regulators in biofilm formation.xlsx by Xiaoyan Yu (319080)

    Published 2025
    “…In particular, the response regulator, AgrA, showed decreased expression but increased malonylation at the K2, K11, and K216 sites during S. aureus biofilm formation, suggesting functional compensation. …”
  4. 9464

    Neither G9a nor SUV39H1 knockdown affects gene expression and epigenetic states of p16 and RASSF1A. by Yutaka Kondo (35816)

    Published 2008
    “…Consistent with the expression status for both genes, DNA methylation is decreased by DAC treatment, whereas no changes are observed in either G9a-KD or SUV-KD cells. …”
  5. 9465

    Effect of small compounds on L55P TTR binding to A-Beta peptide and consequences in TTR proteolytic activity. by Carlos A. Ribeiro (307671)

    Published 2013
    “…<p>A-IEF analysis of L55P alone or in the presence of different compounds known as TTR stabilizers. …”
  6. 9466

    Nivolumab/relatlimab in melanoma: a profile of its use by Arnold Lee (8502113)

    Published 2023
    “…Nivolumab/relatlimab significantly decreased the risk of disease progression or death in comparison with nivolumab monotherapy during a phase 2/3 trial. …”
  7. 9467

    Supplementary Material for: Response Predictors to Calcineurin Inhibitors in Patients with Primary Membranous Nephropathy by Yu X. (2945922)

    Published 2018
    “…<b><i>Results:</i></b> Compared with NR patients, 3 upregulated proteins and 5 downregulated proteins were found to present a twofold change in CR patients’ serum. Serum amyloid A1 protein (SAA1) was further validated by ELISA; it was decreased in patients in the NR group compared with patients in the CR group, but SAA1 in patients in these groups was lower than in healthy controls and minimal change disease patients. …”
  8. 9468

    Stably Integrating an Inducible CRISPR-Cas9 to Aug- ment the Mammalian Immune System to Protect Against Viral Infections by Indeever Madireddy (12513346)

    Published 2022
    “…<br> This luciferase reporter was a marker for viral infection. Six guide RNA sequences<br> were tested, and it was found that luciferase expression decreased by up to 98 per-<br> cent when Cas9 was active relative to a non-targeting control. …”
  9. 9469

    EWSR1-DDIT3 affected recruitment of endogenous C/EBPβ to the C/EBP site within Opn and Col11a2 promoters. by Kayo Suzuki (166737)

    Published 2012
    “…For C/EBPβ, the relative value of immunoprecipitated Opn and Col11a2 promoter fragments significantly decreased after EWSR1-DDIT3 overexpression from 0.71 to 0.30 and 0.76 to 0.35, respectively. …”
  10. 9470

    Baseline characteristics. by Si-Jing Chen (15350263)

    Published 2025
    “…In addition, the CBT-I group reported a greater decrease in depressive (adjusted difference −1.0 [−1.6 to −0.5]; Cohen’s <i>d</i> = 0.53; <i>p</i> < 0.001) and insomnia symptoms (−2.0 [−2.7 to −1.3], <i>d</i> = 0.78; <i>p</i> < 0.001) than the controls at post-intervention and throughout 6-month follow-up. …”
  11. 9471

    Secondary outcome results. by Si-Jing Chen (15350263)

    Published 2025
    “…In addition, the CBT-I group reported a greater decrease in depressive (adjusted difference −1.0 [−1.6 to −0.5]; Cohen’s <i>d</i> = 0.53; <i>p</i> < 0.001) and insomnia symptoms (−2.0 [−2.7 to −1.3], <i>d</i> = 0.78; <i>p</i> < 0.001) than the controls at post-intervention and throughout 6-month follow-up. …”
  12. 9472
  13. 9473
  14. 9474
  15. 9475
  16. 9476
  17. 9477

    EGR1 decreased uPA activity. by Yukihiro Matsunoshita (232591)

    Published 2011
    “…ELISA assay showed that EGR1 decreased uPA activity 0.40-fold in 143B (A). uPA activity was decreased 0.49-fold by EGR1 in Saos-2 (B). …”
  18. 9478
  19. 9479
  20. 9480

    Data_Sheet_1_Inhibition of CD147 Attenuates Stroke-Associated Pneumonia Through Modulating Lung Immune Response in Mice.docx by Rong Jin (201093)

    Published 2019
    “…<p>Background and Purpose: Acute ischemic stroke triggers a profound systemic and local immunodysfunction that increased the susceptibility to infections, especially stroke-associated pneumonia (SAP). …”